Pathogenesis of Aspergillus fumigatus and the Kinetics of Galactomannan in an In Vitro Model of Early Invasive Pulmonary Aspergillosis: Implications for Antifungal Therapy
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Little is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the kinetics of diagnostic markers and the outcome of antifungal therapy. METHODS: An in vitro model of the human alveolus, consisting of a bilayer of human alveolar epithelial and endothelial cells, was developed. An Aspergillus fumigatus strain expressing green fluorescent protein was used. Invasion of the cell bilayer was studied using confocal and electron microscopy. The kinetics of culture, polymerase chain reaction, and galactomannan were determined. Galactomannan was used to measure the antifungal effect of macrophages and amphotericin B. A mathematical model was developed, and results were bridged to humans. RESULTS: A. fumigatus penetrated the cellular bilayer 14-16 h after inoculation. Galactomannan levels were inextricably tied to fungal invasion and were a robust measure of the antifungal effect of macrophages and amphotericin B. Neither amphotericin nor macrophages alone was able to suppress the growth of A. fumigatus; rather, the combination was required. Monte Carlo simulations showed that human dosages of amphotericin B of at least 0.6 mg/kg were required to achieve adequate drug exposure. CONCLUSIONS: This model provides a strategy by which relationships among pathogenesis, immunological effectors, and antifungal drug therapy for invasive pulmonary aspergillosis may be further understood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791 · cited 1×
“immunocompromised hosts and has an overall mortality rate of ∼50% [1–3].”
BackgroundSelf-citationLaboratory diagnosis of invasive aspergillosis
Hope, W., Walsh, T., & Denning, D. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70238-3 · Cited by 495 · cited 2×
“The Aspergillus cell-wall antigen, galactomannan, has been increasingly used as a diagnostic marker for invasive pulmonary aspergillosis (IPA) [4, 5], but there is a relative paucity of data describing the relationship among levels of galactomannan, the pathogenesis of IPA, and its role in…”
BackgroundSelf-citationWasylnka, J. A., & Moore, M. M. (2002) · Infection and Immunity · doi:10.1128/iai.70.6.3156-3163.2002 · Cited by 188 · cited 1×
“fumigatus transformant expressing green fluorescent protein was a gift from Professor Margo Moore (Simon Fraser University, Burnaby, British Columbia, Canada) [9, 10].”
MethodPharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180 · cited 1×
“Previous studies have suggested that the peak concentration: MIC ratio best links drug exposure with outcome [24, 25].”
BackgroundAspergillus fumigatus conidia survive and germinate in acidic organelles of A549 epithelial cells
Wasylnka, J. A., & Moore, M. M. (2003) · Journal of Cell Science · doi:10.1242/jcs.00329 · Cited by 161
Cited by
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundHeng, S. C., Morrissey, O., Chen, S. C.-A., Thursky, K., Manser, R. L., Nation, R. L., Kong, D. C.-M., & Slavin, M. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.804033 · Cited by 133
“alveolar-capillary barrier is likely to be responsible for delayed serum galactomannanemia (Hope et al., 2007), and lower SEN of serum GM in early infection.”
BackgroundInteraction of the pathogenic mold Aspergillus fumigatus with lung epithelial cells
Osherov, N. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00346 · Cited by 96
Intensive care management of influenza-associated pulmonary aspergillosis
Koehler, P., Bassetti, M., Kochanek, M., Shimabukuro-Vornhagen, A., & Cornely, O. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.031 · Cited by 82
The current management landscape: aspergillosis: Table 1.
Maertens, J. A., Blennow, O., Duarte, R. F., & Muñoz, P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw393 · Cited by 29
Metadata
- Authors
- Hope, W. W., Kruhlak, M. J., Lyman, C. A., Petraitiene, R., Petraitis, V., Francesconi, A., Kasai, M., Mickiene, D., Sein, T., Peter, J., Kelaher, A. M., Hughes, J. E., Cotton, M. P., Cotten, C. J., Bacher, J., Tripathi, S., Bermudez, L., Maugel, T. K., Zerfas, P. M., Wingard, J. R., Drusano, G. L., & Walsh, T. J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-02
- Volume
- 195
- Issue
- 3
- Pages
- 455-466
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2114915363
- Cited by
- 128
- References
- 6
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.